Chronic use of renin–angiotensin–aldosterone inhibitors in hypertensive COVID-19 patients: Results from a Spanish registry and meta-analysis
Hypertension is a prevalent condition among SARS-CoV-2 infected patients. Whether renin–angiotensin–aldosterone system (RAAS) inhibitors are beneficial or harmful is controversial. We have performed a national retrospective, nonexperimental comparative study from two tertiary hospitals to evaluate t...
Gespeichert in:
| Veröffentlicht in: | Medicina clinica 2022-04, Vol.158 (7), p.315-323 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 323 |
|---|---|
| container_issue | 7 |
| container_start_page | 315 |
| container_title | Medicina clinica |
| container_volume | 158 |
| creator | Aparisi, Álvaro Catalá, Pablo Amat-Santos, Ignacio J. Marcos-Mangas, Marta López-Otero, Diego Veras, Carlos López-Pais, Javier Cabezón-Villalba, Gonzalo Cacho Antonio, Carla Eugenia Candela, Jordi Antúnez-Muiños, Pablo Gil, José Francisco González Ferrero, Teba Rojas, Gino Pérez-Poza, Marta Uribarri, Aitor Otero-García, Oscar García-Granja, Pablo Elpidio Jiménez Ramos, Víctor Revilla, Ana Dueñas, Carlos Gómez, Itzíar González-Juanatey, José Ramón San Román, J. Alberto |
| description | Hypertension is a prevalent condition among SARS-CoV-2 infected patients. Whether renin–angiotensin–aldosterone system (RAAS) inhibitors are beneficial or harmful is controversial.
We have performed a national retrospective, nonexperimental comparative study from two tertiary hospitals to evaluate the impact of chronic use of RAAS inhibitors in hypertensive COVID-19 patients. A meta-analysis was performed to strengthen our findings.
Of 849 patients, 422 (49.7%) patients were hypertensive and 310 (73.5%) were taking RAAS inhibitors at baseline. Hypertensive patients were older, had more comorbidities, and a greater incidence of respiratory failure (−0.151 [95% CI −0.218, −0.084]). Overall mortality in hypertensive patients was 28.4%, but smaller among those with prescribed RAAS inhibitors before (−0.167 [95% CI −0.220, −0.114]) and during hospitalization (0.090 [−0.008,0.188]). Similar findings were observed after two propensity score matches that evaluated the benefit of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers among hypertensive patients. Multivariate logistic regression analysis of hypertensive patients found that age, diabetes mellitus, C-reactive protein, and renal failure were independently associated with all-cause mortality. On the contrary, ACEIs decreased the risk of death (OR 0.444 [95% CI 0.224–0.881]). Meta-analysis suggested a protective benefit of RAAS inhibitors (OR 0.6 [95% CI 0.42–0.8]) among hypertensive COVID-19.
Our data suggest that RAAS inhibitors may play a protective role in hypertensive COVID-19 patients. This finding was supported by a meta-analysis of the current evidence. Maintaining these medications during hospital stay may not negatively affect COVID-19 outcomes.
La hipertensión es una condición prevalente entre los pacientes infectados por el SARS-CoV-2. Es controvertido si los inhibidores del sistema renina-angiotensina-aldosterona (SRAA) son beneficiosos o perjudiciales.
Hemos desarrollado un estudio comparativo nacional retrospectivo y no experimental en 2 hospitales terciarios para evaluar el impacto del uso crónico de inhibidores del SRAA en pacientes hipertensos con COVID-19. Se realizó un metaanálisis para reforzar los hallazgos.
De 849 pacientes, 422 (49,7%) eran hipertensos y 310 (73,5%) tomaban inhibidores del SRAA al inicio del estudio. Los pacientes hipertensos eran mayores, tenían más comorbilidades y una mayor incidencia de insuficiencia respiratoria (−0,151; IC 95%: [−0,218; − |
| doi_str_mv | 10.1016/j.medcli.2021.04.005 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8101788</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0025775321002098</els_id><sourcerecordid>S0025775321002098</sourcerecordid><originalsourceid>FETCH-LOGICAL-c463t-b8372002b41b080e0f15c0ccc42b845a54ac317bb4e69d3481067bba2b8f7f6e3</originalsourceid><addsrcrecordid>eNp9Udtq3DAQFaWl2ab9g1L0A3YlW7a1eQiUTZsEAoHeXoUsj9davJLRaBf2rZ8QyB_2S6LNJmny0idpmDnnzJlDyEfOcs54_XmVr6Ezo80LVvCciZyx6hWZ8aqRmZzL-WsyY6yosqapyiPyDnG1L0vevCVHpWBSVoWYkZvFELyzhm4QqO9pAGfd3z-32i2tj-DwUI2dxwhpEqh1g21t9AHTlw67CcL93Bbo4vr35VnG53TS0YKLeEK_A27GiLQPfk01_TFpZ3FIMkuLMeyodh1dQ9SZdnrcocX35E2vR4QPD-8x-fXt68_FRXZ1fX65-HKVGVGXMWtl2RTJUCt4yyQD1vPKMGOMKFopKl0JbZLXthVQz7tSSM7qVOnU7Zu-hvKYnB54p027P2RaN-hRTcGuddgpr6162XF2UEu_VYmJN1ImAnEgMMEjBuifsJypfUJqpQ4JqX1CigmVEkqwT891n0CPkfxbDJL7rYWg0KRjGuhsABNV5-3_Fe4A7-aqcw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Chronic use of renin–angiotensin–aldosterone inhibitors in hypertensive COVID-19 patients: Results from a Spanish registry and meta-analysis</title><source>Elsevier ScienceDirect Journals Complete - AutoHoldings</source><source>MEDLINE</source><creator>Aparisi, Álvaro ; Catalá, Pablo ; Amat-Santos, Ignacio J. ; Marcos-Mangas, Marta ; López-Otero, Diego ; Veras, Carlos ; López-Pais, Javier ; Cabezón-Villalba, Gonzalo ; Cacho Antonio, Carla Eugenia ; Candela, Jordi ; Antúnez-Muiños, Pablo ; Gil, José Francisco ; González Ferrero, Teba ; Rojas, Gino ; Pérez-Poza, Marta ; Uribarri, Aitor ; Otero-García, Oscar ; García-Granja, Pablo Elpidio ; Jiménez Ramos, Víctor ; Revilla, Ana ; Dueñas, Carlos ; Gómez, Itzíar ; González-Juanatey, José Ramón ; San Román, J. Alberto</creator><creatorcontrib>Aparisi, Álvaro ; Catalá, Pablo ; Amat-Santos, Ignacio J. ; Marcos-Mangas, Marta ; López-Otero, Diego ; Veras, Carlos ; López-Pais, Javier ; Cabezón-Villalba, Gonzalo ; Cacho Antonio, Carla Eugenia ; Candela, Jordi ; Antúnez-Muiños, Pablo ; Gil, José Francisco ; González Ferrero, Teba ; Rojas, Gino ; Pérez-Poza, Marta ; Uribarri, Aitor ; Otero-García, Oscar ; García-Granja, Pablo Elpidio ; Jiménez Ramos, Víctor ; Revilla, Ana ; Dueñas, Carlos ; Gómez, Itzíar ; González-Juanatey, José Ramón ; San Román, J. Alberto</creatorcontrib><description>Hypertension is a prevalent condition among SARS-CoV-2 infected patients. Whether renin–angiotensin–aldosterone system (RAAS) inhibitors are beneficial or harmful is controversial.
We have performed a national retrospective, nonexperimental comparative study from two tertiary hospitals to evaluate the impact of chronic use of RAAS inhibitors in hypertensive COVID-19 patients. A meta-analysis was performed to strengthen our findings.
Of 849 patients, 422 (49.7%) patients were hypertensive and 310 (73.5%) were taking RAAS inhibitors at baseline. Hypertensive patients were older, had more comorbidities, and a greater incidence of respiratory failure (−0.151 [95% CI −0.218, −0.084]). Overall mortality in hypertensive patients was 28.4%, but smaller among those with prescribed RAAS inhibitors before (−0.167 [95% CI −0.220, −0.114]) and during hospitalization (0.090 [−0.008,0.188]). Similar findings were observed after two propensity score matches that evaluated the benefit of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers among hypertensive patients. Multivariate logistic regression analysis of hypertensive patients found that age, diabetes mellitus, C-reactive protein, and renal failure were independently associated with all-cause mortality. On the contrary, ACEIs decreased the risk of death (OR 0.444 [95% CI 0.224–0.881]). Meta-analysis suggested a protective benefit of RAAS inhibitors (OR 0.6 [95% CI 0.42–0.8]) among hypertensive COVID-19.
Our data suggest that RAAS inhibitors may play a protective role in hypertensive COVID-19 patients. This finding was supported by a meta-analysis of the current evidence. Maintaining these medications during hospital stay may not negatively affect COVID-19 outcomes.
La hipertensión es una condición prevalente entre los pacientes infectados por el SARS-CoV-2. Es controvertido si los inhibidores del sistema renina-angiotensina-aldosterona (SRAA) son beneficiosos o perjudiciales.
Hemos desarrollado un estudio comparativo nacional retrospectivo y no experimental en 2 hospitales terciarios para evaluar el impacto del uso crónico de inhibidores del SRAA en pacientes hipertensos con COVID-19. Se realizó un metaanálisis para reforzar los hallazgos.
De 849 pacientes, 422 (49,7%) eran hipertensos y 310 (73,5%) tomaban inhibidores del SRAA al inicio del estudio. Los pacientes hipertensos eran mayores, tenían más comorbilidades y una mayor incidencia de insuficiencia respiratoria (−0,151; IC 95%: [−0,218; −0,084]). La mortalidad global en los pacientes hipertensos fue del 28,4%, pero fue menor entre los que tenían prescritos inhibidores del SRAA antes (−0,167; IC 95%: [−0,220; −0,114]) y durante la hospitalización (0,090; [−0,008; 0,188]). Se observaron hallazgos similares tras 2 emparejamientos de puntuación de propensión que evaluaron el beneficio de los inhibidores de la enzima convertidora de angiotensina y los bloqueadores de los receptores de angiotensina entre los pacientes hipertensos. El análisis de regresión logística multivariante de los pacientes hipertensos reveló que la edad, la diabetes mellitus, la proteína C reactiva y la insuficiencia renal se asociaban de forma independiente con la mortalidad por todas las causas. Por el contrario, los inhibidores de la enzima convertidora de angiotensina disminuyeron el riesgo de muerte (OR 0,444; IC 95%: 0,224-0,881). El metaanálisis indicó un beneficio protector de los inhibidores del SRAA (OR 0,6; IC 95%: 0,42-0,8) entre los hipertensos con COVID-19.
Nuestros datos indican que los inhibidores del SRAA pueden desempeñar un papel protector en los pacientes hipertensos con COVID-19. Este hallazgo fue apoyado por un metaanálisis de la evidencia actual. Su mantenimiento durante la estancia hospitalaria puede no afectar negativamente a los resultados de la COVID-19.</description><identifier>ISSN: 0025-7753</identifier><identifier>EISSN: 1578-8989</identifier><identifier>DOI: 10.1016/j.medcli.2021.04.005</identifier><identifier>PMID: 34088524</identifier><language>eng</language><publisher>Spain: Elsevier España, S.L.U</publisher><subject>Aldosterone - pharmacology ; Aldosterone - therapeutic use ; Angiotensin II receptor blockers ; Angiotensin Receptor Antagonists - pharmacology ; Angiotensin Receptor Antagonists - therapeutic use ; Angiotensin-converting-enzyme inhibitors ; Angiotensins - pharmacology ; Angiotensins - therapeutic use ; Antagonistas de los receptores de la angiotensina II ; Antihypertensive Agents - therapeutic use ; COVID-19 ; Hipertensión arterial ; Humans ; Hypertension ; Hypertension - complications ; Hypertension - drug therapy ; Inhibidores de la enzima convertidora de angiotensina ; Meta-analysis ; Metaanális ; Mineralocorticoid Receptor Antagonists - therapeutic use ; Original ; Registries ; Renin - pharmacology ; Renin - therapeutic use ; Renin-Angiotensin System ; Retrospective Studies ; SARS-CoV-2</subject><ispartof>Medicina clinica, 2022-04, Vol.158 (7), p.315-323</ispartof><rights>2021 Elsevier España, S.L.U.</rights><rights>Copyright © 2021 Elsevier España, S.L.U. All rights reserved.</rights><rights>2021 Elsevier España, S.L.U. All rights reserved. 2021 Elsevier España, S.L.U.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c463t-b8372002b41b080e0f15c0ccc42b845a54ac317bb4e69d3481067bba2b8f7f6e3</citedby><cites>FETCH-LOGICAL-c463t-b8372002b41b080e0f15c0ccc42b845a54ac317bb4e69d3481067bba2b8f7f6e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.medcli.2021.04.005$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,778,782,883,3539,27907,27908,45978</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34088524$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Aparisi, Álvaro</creatorcontrib><creatorcontrib>Catalá, Pablo</creatorcontrib><creatorcontrib>Amat-Santos, Ignacio J.</creatorcontrib><creatorcontrib>Marcos-Mangas, Marta</creatorcontrib><creatorcontrib>López-Otero, Diego</creatorcontrib><creatorcontrib>Veras, Carlos</creatorcontrib><creatorcontrib>López-Pais, Javier</creatorcontrib><creatorcontrib>Cabezón-Villalba, Gonzalo</creatorcontrib><creatorcontrib>Cacho Antonio, Carla Eugenia</creatorcontrib><creatorcontrib>Candela, Jordi</creatorcontrib><creatorcontrib>Antúnez-Muiños, Pablo</creatorcontrib><creatorcontrib>Gil, José Francisco</creatorcontrib><creatorcontrib>González Ferrero, Teba</creatorcontrib><creatorcontrib>Rojas, Gino</creatorcontrib><creatorcontrib>Pérez-Poza, Marta</creatorcontrib><creatorcontrib>Uribarri, Aitor</creatorcontrib><creatorcontrib>Otero-García, Oscar</creatorcontrib><creatorcontrib>García-Granja, Pablo Elpidio</creatorcontrib><creatorcontrib>Jiménez Ramos, Víctor</creatorcontrib><creatorcontrib>Revilla, Ana</creatorcontrib><creatorcontrib>Dueñas, Carlos</creatorcontrib><creatorcontrib>Gómez, Itzíar</creatorcontrib><creatorcontrib>González-Juanatey, José Ramón</creatorcontrib><creatorcontrib>San Román, J. Alberto</creatorcontrib><title>Chronic use of renin–angiotensin–aldosterone inhibitors in hypertensive COVID-19 patients: Results from a Spanish registry and meta-analysis</title><title>Medicina clinica</title><addtitle>Med Clin (Barc)</addtitle><description>Hypertension is a prevalent condition among SARS-CoV-2 infected patients. Whether renin–angiotensin–aldosterone system (RAAS) inhibitors are beneficial or harmful is controversial.
We have performed a national retrospective, nonexperimental comparative study from two tertiary hospitals to evaluate the impact of chronic use of RAAS inhibitors in hypertensive COVID-19 patients. A meta-analysis was performed to strengthen our findings.
Of 849 patients, 422 (49.7%) patients were hypertensive and 310 (73.5%) were taking RAAS inhibitors at baseline. Hypertensive patients were older, had more comorbidities, and a greater incidence of respiratory failure (−0.151 [95% CI −0.218, −0.084]). Overall mortality in hypertensive patients was 28.4%, but smaller among those with prescribed RAAS inhibitors before (−0.167 [95% CI −0.220, −0.114]) and during hospitalization (0.090 [−0.008,0.188]). Similar findings were observed after two propensity score matches that evaluated the benefit of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers among hypertensive patients. Multivariate logistic regression analysis of hypertensive patients found that age, diabetes mellitus, C-reactive protein, and renal failure were independently associated with all-cause mortality. On the contrary, ACEIs decreased the risk of death (OR 0.444 [95% CI 0.224–0.881]). Meta-analysis suggested a protective benefit of RAAS inhibitors (OR 0.6 [95% CI 0.42–0.8]) among hypertensive COVID-19.
Our data suggest that RAAS inhibitors may play a protective role in hypertensive COVID-19 patients. This finding was supported by a meta-analysis of the current evidence. Maintaining these medications during hospital stay may not negatively affect COVID-19 outcomes.
La hipertensión es una condición prevalente entre los pacientes infectados por el SARS-CoV-2. Es controvertido si los inhibidores del sistema renina-angiotensina-aldosterona (SRAA) son beneficiosos o perjudiciales.
Hemos desarrollado un estudio comparativo nacional retrospectivo y no experimental en 2 hospitales terciarios para evaluar el impacto del uso crónico de inhibidores del SRAA en pacientes hipertensos con COVID-19. Se realizó un metaanálisis para reforzar los hallazgos.
De 849 pacientes, 422 (49,7%) eran hipertensos y 310 (73,5%) tomaban inhibidores del SRAA al inicio del estudio. Los pacientes hipertensos eran mayores, tenían más comorbilidades y una mayor incidencia de insuficiencia respiratoria (−0,151; IC 95%: [−0,218; −0,084]). La mortalidad global en los pacientes hipertensos fue del 28,4%, pero fue menor entre los que tenían prescritos inhibidores del SRAA antes (−0,167; IC 95%: [−0,220; −0,114]) y durante la hospitalización (0,090; [−0,008; 0,188]). Se observaron hallazgos similares tras 2 emparejamientos de puntuación de propensión que evaluaron el beneficio de los inhibidores de la enzima convertidora de angiotensina y los bloqueadores de los receptores de angiotensina entre los pacientes hipertensos. El análisis de regresión logística multivariante de los pacientes hipertensos reveló que la edad, la diabetes mellitus, la proteína C reactiva y la insuficiencia renal se asociaban de forma independiente con la mortalidad por todas las causas. Por el contrario, los inhibidores de la enzima convertidora de angiotensina disminuyeron el riesgo de muerte (OR 0,444; IC 95%: 0,224-0,881). El metaanálisis indicó un beneficio protector de los inhibidores del SRAA (OR 0,6; IC 95%: 0,42-0,8) entre los hipertensos con COVID-19.
Nuestros datos indican que los inhibidores del SRAA pueden desempeñar un papel protector en los pacientes hipertensos con COVID-19. Este hallazgo fue apoyado por un metaanálisis de la evidencia actual. Su mantenimiento durante la estancia hospitalaria puede no afectar negativamente a los resultados de la COVID-19.</description><subject>Aldosterone - pharmacology</subject><subject>Aldosterone - therapeutic use</subject><subject>Angiotensin II receptor blockers</subject><subject>Angiotensin Receptor Antagonists - pharmacology</subject><subject>Angiotensin Receptor Antagonists - therapeutic use</subject><subject>Angiotensin-converting-enzyme inhibitors</subject><subject>Angiotensins - pharmacology</subject><subject>Angiotensins - therapeutic use</subject><subject>Antagonistas de los receptores de la angiotensina II</subject><subject>Antihypertensive Agents - therapeutic use</subject><subject>COVID-19</subject><subject>Hipertensión arterial</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Hypertension - complications</subject><subject>Hypertension - drug therapy</subject><subject>Inhibidores de la enzima convertidora de angiotensina</subject><subject>Meta-analysis</subject><subject>Metaanális</subject><subject>Mineralocorticoid Receptor Antagonists - therapeutic use</subject><subject>Original</subject><subject>Registries</subject><subject>Renin - pharmacology</subject><subject>Renin - therapeutic use</subject><subject>Renin-Angiotensin System</subject><subject>Retrospective Studies</subject><subject>SARS-CoV-2</subject><issn>0025-7753</issn><issn>1578-8989</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9Udtq3DAQFaWl2ab9g1L0A3YlW7a1eQiUTZsEAoHeXoUsj9davJLRaBf2rZ8QyB_2S6LNJmny0idpmDnnzJlDyEfOcs54_XmVr6Ezo80LVvCciZyx6hWZ8aqRmZzL-WsyY6yosqapyiPyDnG1L0vevCVHpWBSVoWYkZvFELyzhm4QqO9pAGfd3z-32i2tj-DwUI2dxwhpEqh1g21t9AHTlw67CcL93Bbo4vr35VnG53TS0YKLeEK_A27GiLQPfk01_TFpZ3FIMkuLMeyodh1dQ9SZdnrcocX35E2vR4QPD-8x-fXt68_FRXZ1fX65-HKVGVGXMWtl2RTJUCt4yyQD1vPKMGOMKFopKl0JbZLXthVQz7tSSM7qVOnU7Zu-hvKYnB54p027P2RaN-hRTcGuddgpr6162XF2UEu_VYmJN1ImAnEgMMEjBuifsJypfUJqpQ4JqX1CigmVEkqwT891n0CPkfxbDJL7rYWg0KRjGuhsABNV5-3_Fe4A7-aqcw</recordid><startdate>20220408</startdate><enddate>20220408</enddate><creator>Aparisi, Álvaro</creator><creator>Catalá, Pablo</creator><creator>Amat-Santos, Ignacio J.</creator><creator>Marcos-Mangas, Marta</creator><creator>López-Otero, Diego</creator><creator>Veras, Carlos</creator><creator>López-Pais, Javier</creator><creator>Cabezón-Villalba, Gonzalo</creator><creator>Cacho Antonio, Carla Eugenia</creator><creator>Candela, Jordi</creator><creator>Antúnez-Muiños, Pablo</creator><creator>Gil, José Francisco</creator><creator>González Ferrero, Teba</creator><creator>Rojas, Gino</creator><creator>Pérez-Poza, Marta</creator><creator>Uribarri, Aitor</creator><creator>Otero-García, Oscar</creator><creator>García-Granja, Pablo Elpidio</creator><creator>Jiménez Ramos, Víctor</creator><creator>Revilla, Ana</creator><creator>Dueñas, Carlos</creator><creator>Gómez, Itzíar</creator><creator>González-Juanatey, José Ramón</creator><creator>San Román, J. Alberto</creator><general>Elsevier España, S.L.U</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20220408</creationdate><title>Chronic use of renin–angiotensin–aldosterone inhibitors in hypertensive COVID-19 patients: Results from a Spanish registry and meta-analysis</title><author>Aparisi, Álvaro ; Catalá, Pablo ; Amat-Santos, Ignacio J. ; Marcos-Mangas, Marta ; López-Otero, Diego ; Veras, Carlos ; López-Pais, Javier ; Cabezón-Villalba, Gonzalo ; Cacho Antonio, Carla Eugenia ; Candela, Jordi ; Antúnez-Muiños, Pablo ; Gil, José Francisco ; González Ferrero, Teba ; Rojas, Gino ; Pérez-Poza, Marta ; Uribarri, Aitor ; Otero-García, Oscar ; García-Granja, Pablo Elpidio ; Jiménez Ramos, Víctor ; Revilla, Ana ; Dueñas, Carlos ; Gómez, Itzíar ; González-Juanatey, José Ramón ; San Román, J. Alberto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c463t-b8372002b41b080e0f15c0ccc42b845a54ac317bb4e69d3481067bba2b8f7f6e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Aldosterone - pharmacology</topic><topic>Aldosterone - therapeutic use</topic><topic>Angiotensin II receptor blockers</topic><topic>Angiotensin Receptor Antagonists - pharmacology</topic><topic>Angiotensin Receptor Antagonists - therapeutic use</topic><topic>Angiotensin-converting-enzyme inhibitors</topic><topic>Angiotensins - pharmacology</topic><topic>Angiotensins - therapeutic use</topic><topic>Antagonistas de los receptores de la angiotensina II</topic><topic>Antihypertensive Agents - therapeutic use</topic><topic>COVID-19</topic><topic>Hipertensión arterial</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Hypertension - complications</topic><topic>Hypertension - drug therapy</topic><topic>Inhibidores de la enzima convertidora de angiotensina</topic><topic>Meta-analysis</topic><topic>Metaanális</topic><topic>Mineralocorticoid Receptor Antagonists - therapeutic use</topic><topic>Original</topic><topic>Registries</topic><topic>Renin - pharmacology</topic><topic>Renin - therapeutic use</topic><topic>Renin-Angiotensin System</topic><topic>Retrospective Studies</topic><topic>SARS-CoV-2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aparisi, Álvaro</creatorcontrib><creatorcontrib>Catalá, Pablo</creatorcontrib><creatorcontrib>Amat-Santos, Ignacio J.</creatorcontrib><creatorcontrib>Marcos-Mangas, Marta</creatorcontrib><creatorcontrib>López-Otero, Diego</creatorcontrib><creatorcontrib>Veras, Carlos</creatorcontrib><creatorcontrib>López-Pais, Javier</creatorcontrib><creatorcontrib>Cabezón-Villalba, Gonzalo</creatorcontrib><creatorcontrib>Cacho Antonio, Carla Eugenia</creatorcontrib><creatorcontrib>Candela, Jordi</creatorcontrib><creatorcontrib>Antúnez-Muiños, Pablo</creatorcontrib><creatorcontrib>Gil, José Francisco</creatorcontrib><creatorcontrib>González Ferrero, Teba</creatorcontrib><creatorcontrib>Rojas, Gino</creatorcontrib><creatorcontrib>Pérez-Poza, Marta</creatorcontrib><creatorcontrib>Uribarri, Aitor</creatorcontrib><creatorcontrib>Otero-García, Oscar</creatorcontrib><creatorcontrib>García-Granja, Pablo Elpidio</creatorcontrib><creatorcontrib>Jiménez Ramos, Víctor</creatorcontrib><creatorcontrib>Revilla, Ana</creatorcontrib><creatorcontrib>Dueñas, Carlos</creatorcontrib><creatorcontrib>Gómez, Itzíar</creatorcontrib><creatorcontrib>González-Juanatey, José Ramón</creatorcontrib><creatorcontrib>San Román, J. Alberto</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicina clinica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aparisi, Álvaro</au><au>Catalá, Pablo</au><au>Amat-Santos, Ignacio J.</au><au>Marcos-Mangas, Marta</au><au>López-Otero, Diego</au><au>Veras, Carlos</au><au>López-Pais, Javier</au><au>Cabezón-Villalba, Gonzalo</au><au>Cacho Antonio, Carla Eugenia</au><au>Candela, Jordi</au><au>Antúnez-Muiños, Pablo</au><au>Gil, José Francisco</au><au>González Ferrero, Teba</au><au>Rojas, Gino</au><au>Pérez-Poza, Marta</au><au>Uribarri, Aitor</au><au>Otero-García, Oscar</au><au>García-Granja, Pablo Elpidio</au><au>Jiménez Ramos, Víctor</au><au>Revilla, Ana</au><au>Dueñas, Carlos</au><au>Gómez, Itzíar</au><au>González-Juanatey, José Ramón</au><au>San Román, J. Alberto</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chronic use of renin–angiotensin–aldosterone inhibitors in hypertensive COVID-19 patients: Results from a Spanish registry and meta-analysis</atitle><jtitle>Medicina clinica</jtitle><addtitle>Med Clin (Barc)</addtitle><date>2022-04-08</date><risdate>2022</risdate><volume>158</volume><issue>7</issue><spage>315</spage><epage>323</epage><pages>315-323</pages><issn>0025-7753</issn><eissn>1578-8989</eissn><abstract>Hypertension is a prevalent condition among SARS-CoV-2 infected patients. Whether renin–angiotensin–aldosterone system (RAAS) inhibitors are beneficial or harmful is controversial.
We have performed a national retrospective, nonexperimental comparative study from two tertiary hospitals to evaluate the impact of chronic use of RAAS inhibitors in hypertensive COVID-19 patients. A meta-analysis was performed to strengthen our findings.
Of 849 patients, 422 (49.7%) patients were hypertensive and 310 (73.5%) were taking RAAS inhibitors at baseline. Hypertensive patients were older, had more comorbidities, and a greater incidence of respiratory failure (−0.151 [95% CI −0.218, −0.084]). Overall mortality in hypertensive patients was 28.4%, but smaller among those with prescribed RAAS inhibitors before (−0.167 [95% CI −0.220, −0.114]) and during hospitalization (0.090 [−0.008,0.188]). Similar findings were observed after two propensity score matches that evaluated the benefit of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers among hypertensive patients. Multivariate logistic regression analysis of hypertensive patients found that age, diabetes mellitus, C-reactive protein, and renal failure were independently associated with all-cause mortality. On the contrary, ACEIs decreased the risk of death (OR 0.444 [95% CI 0.224–0.881]). Meta-analysis suggested a protective benefit of RAAS inhibitors (OR 0.6 [95% CI 0.42–0.8]) among hypertensive COVID-19.
Our data suggest that RAAS inhibitors may play a protective role in hypertensive COVID-19 patients. This finding was supported by a meta-analysis of the current evidence. Maintaining these medications during hospital stay may not negatively affect COVID-19 outcomes.
La hipertensión es una condición prevalente entre los pacientes infectados por el SARS-CoV-2. Es controvertido si los inhibidores del sistema renina-angiotensina-aldosterona (SRAA) son beneficiosos o perjudiciales.
Hemos desarrollado un estudio comparativo nacional retrospectivo y no experimental en 2 hospitales terciarios para evaluar el impacto del uso crónico de inhibidores del SRAA en pacientes hipertensos con COVID-19. Se realizó un metaanálisis para reforzar los hallazgos.
De 849 pacientes, 422 (49,7%) eran hipertensos y 310 (73,5%) tomaban inhibidores del SRAA al inicio del estudio. Los pacientes hipertensos eran mayores, tenían más comorbilidades y una mayor incidencia de insuficiencia respiratoria (−0,151; IC 95%: [−0,218; −0,084]). La mortalidad global en los pacientes hipertensos fue del 28,4%, pero fue menor entre los que tenían prescritos inhibidores del SRAA antes (−0,167; IC 95%: [−0,220; −0,114]) y durante la hospitalización (0,090; [−0,008; 0,188]). Se observaron hallazgos similares tras 2 emparejamientos de puntuación de propensión que evaluaron el beneficio de los inhibidores de la enzima convertidora de angiotensina y los bloqueadores de los receptores de angiotensina entre los pacientes hipertensos. El análisis de regresión logística multivariante de los pacientes hipertensos reveló que la edad, la diabetes mellitus, la proteína C reactiva y la insuficiencia renal se asociaban de forma independiente con la mortalidad por todas las causas. Por el contrario, los inhibidores de la enzima convertidora de angiotensina disminuyeron el riesgo de muerte (OR 0,444; IC 95%: 0,224-0,881). El metaanálisis indicó un beneficio protector de los inhibidores del SRAA (OR 0,6; IC 95%: 0,42-0,8) entre los hipertensos con COVID-19.
Nuestros datos indican que los inhibidores del SRAA pueden desempeñar un papel protector en los pacientes hipertensos con COVID-19. Este hallazgo fue apoyado por un metaanálisis de la evidencia actual. Su mantenimiento durante la estancia hospitalaria puede no afectar negativamente a los resultados de la COVID-19.</abstract><cop>Spain</cop><pub>Elsevier España, S.L.U</pub><pmid>34088524</pmid><doi>10.1016/j.medcli.2021.04.005</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0025-7753 |
| ispartof | Medicina clinica, 2022-04, Vol.158 (7), p.315-323 |
| issn | 0025-7753 1578-8989 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8101788 |
| source | Elsevier ScienceDirect Journals Complete - AutoHoldings; MEDLINE |
| subjects | Aldosterone - pharmacology Aldosterone - therapeutic use Angiotensin II receptor blockers Angiotensin Receptor Antagonists - pharmacology Angiotensin Receptor Antagonists - therapeutic use Angiotensin-converting-enzyme inhibitors Angiotensins - pharmacology Angiotensins - therapeutic use Antagonistas de los receptores de la angiotensina II Antihypertensive Agents - therapeutic use COVID-19 Hipertensión arterial Humans Hypertension Hypertension - complications Hypertension - drug therapy Inhibidores de la enzima convertidora de angiotensina Meta-analysis Metaanális Mineralocorticoid Receptor Antagonists - therapeutic use Original Registries Renin - pharmacology Renin - therapeutic use Renin-Angiotensin System Retrospective Studies SARS-CoV-2 |
| title | Chronic use of renin–angiotensin–aldosterone inhibitors in hypertensive COVID-19 patients: Results from a Spanish registry and meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T15%3A58%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chronic%20use%20of%20renin%E2%80%93angiotensin%E2%80%93aldosterone%20inhibitors%20in%20hypertensive%20COVID-19%20patients:%20Results%20from%20a%20Spanish%20registry%20and%20meta-analysis&rft.jtitle=Medicina%20clinica&rft.au=Aparisi,%20%C3%81lvaro&rft.date=2022-04-08&rft.volume=158&rft.issue=7&rft.spage=315&rft.epage=323&rft.pages=315-323&rft.issn=0025-7753&rft.eissn=1578-8989&rft_id=info:doi/10.1016/j.medcli.2021.04.005&rft_dat=%3Celsevier_pubme%3ES0025775321002098%3C/elsevier_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/34088524&rft_els_id=S0025775321002098&rfr_iscdi=true |